Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132117 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
NCT02132117 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 445 participants.
The verdict
NCT02132117, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
Interventions
- DRUG Oxymetazoline HCL Cream 1.0%
- DRUG Vehicle to Oxymetazoline HCL Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02132117
The ClinicalTrials.gov registry entry for NCT02132117 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxymetazoline HCL Cream 1.0% is the first listed.
NCT02132117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02132117 about?
NCT02132117 is a clinical study titled "Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea". This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
What is the current status of trial NCT02132117?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2014-06. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02132117?
The interventions under investigation include: Oxymetazoline HCL Cream 1.0% (DRUG), Vehicle to Oxymetazoline HCL Cream (DRUG).
Who is sponsoring clinical trial NCT02132117?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.